SG11201900133WA - Adrenomedullin for assessing congestion in a subject with acute heart failure - Google Patents
Adrenomedullin for assessing congestion in a subject with acute heart failureInfo
- Publication number
- SG11201900133WA SG11201900133WA SG11201900133WA SG11201900133WA SG11201900133WA SG 11201900133W A SG11201900133W A SG 11201900133WA SG 11201900133W A SG11201900133W A SG 11201900133WA SG 11201900133W A SG11201900133W A SG 11201900133WA SG 11201900133W A SG11201900133W A SG 11201900133WA
- Authority
- SG
- Singapore
- Prior art keywords
- subject
- congestion
- international
- intervention
- heart failure
- Prior art date
Links
- 206010007556 Cardiac failure acute Diseases 0.000 title abstract 3
- 102000004379 Adrenomedullin Human genes 0.000 title abstract 2
- 101800004616 Adrenomedullin Proteins 0.000 title abstract 2
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 5
- 238000012544 monitoring process Methods 0.000 abstract 3
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000034567 proadrenomedullin Human genes 0.000 abstract 1
- 108010012004 proadrenomedullin Proteins 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 DOI HIM 011101 0 01111111111 11111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/007588 Al 11 January 2018 (11.01.2018) W I PO I PCT (51) International Patent Classification: G01N 33/68 (2006.01) G01N 33/74 (2006.01) Published: — with international search report (Art. 21(3)) (21) International Application Number: — with sequence listing part of description (Rule 5.2(a)) PCT/EP2017/067091 (22) International Filing Date: 07 July 2017 (07.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16178725.4 08 July 2016 (08.07.2016) EP 16199092.4 16 November 2016 (16.11.2016) EP (71) Applicant: SPHINGOTEC GMBH [DE/DE]; Neuendorf- str. 15 A, 16761 Hennigsdorf (DE). (72) Inventors: BERGMANN, Andreas; Am Rosenanger 78, 13465 Berlin (DE). VOORS, Adriaan; Scheperij 5, 9312VH Nietap (NL). (74) Agent: BOEHMERT & BOEHMERT; Dr. Ute Kilger, Hollerallee 32, 28209 Bremen (DE). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) ,_ 1 (54) Title: ADRENOMEDULLIN FOR ASSESSING CONGESTION IN A SUBJECT WITH ACUTE HEART FAILURE (57) : Subject matter of the present invention is a method for a) diagnosing congestion or assessing or monitoring the extent GO of congestion in a subject or, b) predicting or determining or monitoring need of therapy or intervention or predicting or determining = or ir) monitoring the success of a therapy or intervention of congestion or guiding a therapy or intervention in a subject or, c) predicting N decongestion or residual congestion after therapy or intervention of congestion in a subject or, d) assessing decongestion or residual 0 congestion after therapy or intervention of congestion in a subject or, e) assessing the decision on hospital discharge of a subject, wherein 0 --.... said subject is subject having acute heart failure that is either new-onset AHF or acute decompensated HF or acute decompensated Ot chronic HF or wherein said subject is a subject having chronic heart failure with worsening signs/symptoms of chronic heart failure 1-1 O and wherein Pro-Adrenomedullin or fragments thereof of at least 5 amino acids is used as an early surrogate marker for congestion. ei C
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16178725 | 2016-07-08 | ||
| EP16199092 | 2016-11-16 | ||
| PCT/EP2017/067091 WO2018007588A1 (en) | 2016-07-08 | 2017-07-07 | Adrenomedullin for assessing congestion in a subject with acute heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900133WA true SG11201900133WA (en) | 2019-02-27 |
Family
ID=59366410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900133WA SG11201900133WA (en) | 2016-07-08 | 2017-07-07 | Adrenomedullin for assessing congestion in a subject with acute heart failure |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190376985A1 (en) |
| EP (2) | EP4231018A3 (en) |
| JP (3) | JP7191813B2 (en) |
| CN (1) | CN109716136B (en) |
| AU (1) | AU2017294549C1 (en) |
| BR (1) | BR112019000199A2 (en) |
| ES (1) | ES2948446T3 (en) |
| MX (1) | MX2019000003A (en) |
| RU (1) | RU2019103403A (en) |
| SG (1) | SG11201900133WA (en) |
| WO (1) | WO2018007588A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3438668A1 (en) | 2017-08-04 | 2019-02-06 | B.R.A.H.M.S GmbH | Diagnosis and risk stratification of fungal infections |
| JP7346389B2 (en) | 2017-09-13 | 2023-09-19 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Proadrenomedullin as a marker of abnormal platelet levels |
| EP3502706A1 (en) | 2017-12-20 | 2019-06-26 | B.R.A.H.M.S GmbH | Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin |
| WO2019154900A1 (en) * | 2018-02-08 | 2019-08-15 | Sphingotec Gmbh | Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia |
| EP3608673A1 (en) * | 2018-08-08 | 2020-02-12 | B.R.A.H.M.S GmbH | Pro-adm for prognosing the risk of a medical condition requiring hospitalization in patients with symptoms of infectious disease |
| EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE139258T1 (en) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | GENERATION OF XENOGENE ANTIBODIES |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0585287T3 (en) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Process for producing specific binding pair elements |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | Transgenic non-human animals capable of producing heterologous antibodies |
| JP2774769B2 (en) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | Adrenomedullin |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| JP2005508623A (en) | 2001-08-30 | 2005-04-07 | バイオレクシス ファーマシューティカル コーポレイション | Modified transferrin fusion protein |
| PT1941867E (en) | 2002-06-07 | 2012-02-16 | Dyax Corp | Modified kunitz domain polypeptide |
| AU2004284090A1 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | LDL receptor class A and EGF domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| EP2314308A1 (en) | 2004-09-21 | 2011-04-27 | BioNTech AG | Use of microproteins as tryptase inhibitors |
| US9012151B2 (en) * | 2006-11-09 | 2015-04-21 | B.R.A.H.M.S. Gmbh | Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin |
| DE102006060112A1 (en) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnosis and risk stratification using the new marker CT-proADM |
| DK2231860T3 (en) | 2007-12-19 | 2011-12-05 | Affibody Ab | Polypeptide derived protein A and capable of binding PDGF |
| WO2010060748A1 (en) | 2008-11-03 | 2010-06-03 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| CN102317790B (en) * | 2008-11-11 | 2014-12-10 | B.R.A.H.M.S有限公司 | Use of ADM in the manufacture of a formulation for the evaluation of heart failure and/or shortness of breath |
| ES2643033T3 (en) * | 2009-05-05 | 2017-11-21 | B.R.A.H.M.S Gmbh | Stratification based on vasoactive hormone in patients suffering from diseases related to endothelial function / dysfunction |
| CN102869678A (en) | 2009-08-27 | 2013-01-09 | 科瓦根股份公司 | Il-17 binding compounds and medical uses thereof |
| EP2367843B1 (en) | 2009-12-14 | 2014-10-08 | Scil Proteins GmbH | Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin |
| HRP20190689T1 (en) | 2010-06-08 | 2019-06-14 | Pieris Pharmaceuticals Gmbh | Tear lipocalin muteins binding il-4 r alpha |
| EP2594588B1 (en) * | 2011-11-16 | 2014-05-21 | AdrenoMed AG | Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or an anti-ADM non-Ig protein scaffold for use in therapy |
| WO2014147153A1 (en) * | 2013-03-20 | 2014-09-25 | Sphingotec Gmbh | Adrenomedullin to guide therapy of blood pressure decline |
| JP7270912B2 (en) * | 2017-05-22 | 2023-05-11 | 東ソー株式会社 | Information provision method for prognosis prediction by adrenomedullin concentration fluctuation and its reagent |
-
2017
- 2017-07-07 MX MX2019000003A patent/MX2019000003A/en unknown
- 2017-07-07 RU RU2019103403A patent/RU2019103403A/en unknown
- 2017-07-07 AU AU2017294549A patent/AU2017294549C1/en active Active
- 2017-07-07 US US16/315,805 patent/US20190376985A1/en active Pending
- 2017-07-07 WO PCT/EP2017/067091 patent/WO2018007588A1/en not_active Ceased
- 2017-07-07 EP EP23167412.8A patent/EP4231018A3/en not_active Withdrawn
- 2017-07-07 CN CN201780055476.7A patent/CN109716136B/en active Active
- 2017-07-07 ES ES17740693T patent/ES2948446T3/en active Active
- 2017-07-07 BR BR112019000199-9A patent/BR112019000199A2/en unknown
- 2017-07-07 JP JP2019500262A patent/JP7191813B2/en active Active
- 2017-07-07 SG SG11201900133WA patent/SG11201900133WA/en unknown
- 2017-07-07 EP EP17740693.1A patent/EP3482208B1/en active Active
-
2022
- 2022-05-25 JP JP2022085204A patent/JP7654597B2/en active Active
-
2024
- 2024-06-18 JP JP2024098031A patent/JP2024163910A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022122924A (en) | 2022-08-23 |
| RU2019103403A3 (en) | 2020-10-01 |
| US20190376985A1 (en) | 2019-12-12 |
| MX2019000003A (en) | 2019-08-29 |
| JP2019530851A (en) | 2019-10-24 |
| JP7654597B2 (en) | 2025-04-01 |
| ES2948446T3 (en) | 2023-09-12 |
| EP3482208A1 (en) | 2019-05-15 |
| EP3482208B1 (en) | 2023-04-12 |
| BR112019000199A2 (en) | 2019-04-16 |
| JP2024163910A (en) | 2024-11-22 |
| CA3030214A1 (en) | 2018-01-11 |
| JP7191813B2 (en) | 2022-12-19 |
| AU2017294549A1 (en) | 2019-01-24 |
| AU2017294549B2 (en) | 2023-04-20 |
| EP4231018A2 (en) | 2023-08-23 |
| CN109716136B (en) | 2023-09-22 |
| AU2017294549C1 (en) | 2023-10-26 |
| CN109716136A (en) | 2019-05-03 |
| WO2018007588A1 (en) | 2018-01-11 |
| RU2019103403A (en) | 2020-08-10 |
| EP4231018A3 (en) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900133WA (en) | Adrenomedullin for assessing congestion in a subject with acute heart failure | |
| SG11201809252YA (en) | Methods for determining dpp3 and therapeutic methods | |
| SG11201808152PA (en) | Dna antibody constructs and method of using same | |
| SG11201808820QA (en) | Methods and kits for the diagnosis and risk stratification of patients with ischemia | |
| SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
| SG11201900468YA (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
| SG11201900975XA (en) | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same | |
| SG11201803666WA (en) | Single image detection | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201901418XA (en) | Heart valve docking system | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201807501UA (en) | Method and system for imaging | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201900992XA (en) | Computer architecture and method for recommending asset repairs | |
| SG11201806401YA (en) | G protein-coupled receptor (gpcr) modulation by imipridones | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201809789SA (en) | Dna monoclonal antibodies targeting checkpoint molecules | |
| SG11201803642WA (en) | Bacteria-based protein delivery | |
| SG11201909882SA (en) | Targeted neoepitope vectors and methods therefor | |
| SG11201805496PA (en) | An immunoassay for the diagnosis of viral infections | |
| SG11201907199QA (en) | Cancer treatment | |
| SG11201806432PA (en) | Methods for assessing risk of developing colorectal cancer | |
| SG11201906778RA (en) | Improved methods for assessing risk of developing breast cancer |